Atlas Legacy Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.82M Buy
1,579
+434
+38% +$443K 0.27% 62
2026
Q1
$1.05M Sell
1,145
-401
-26% -$407K 0.19% 81
2025
Q4
$1.65M Buy
1,546
+79
+5% +$75.5K 0.29% 64
2025
Q3
$1.12M Buy
1,467
+713
+95% +$531K 0.22% 73
2025
Q2
$588K Sell
754
-17
-2% -$13.2K 0.13% 106
2025
Q1
$637K Buy
771
+7
+0.9% +$5.83K 0.16% 88
2024
Q4
$590K Buy
+764
New +$633K 0.14% 91

Other funds holding LLY

Atlas Legacy Advisors's LLY Position: Q2 2026 in Review

Atlas Legacy Advisors increased its Eli Lilly (LLY) stake by 38% in Q2 2026, buying an estimated $443K and bringing the position to 1,579 shares worth $1.82M. The position accounts for 0.27% of the portfolio, ranked #62.

Atlas Legacy Advisors first reported a position in LLY in Q4 2024 and has held it in 7 quarters since. 4,642 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Atlas Legacy Advisors held 1,579 shares of Eli Lilly worth $1.82M as of Q2 2026.
  • Atlas Legacy Advisors bought 434 Eli Lilly shares in Q2 2026, an estimated $443K.
  • Eli Lilly made up 0.27% of Atlas Legacy Advisors's portfolio in Q2 2026, its #62 holding.
  • Atlas Legacy Advisors first reported a position in Eli Lilly in Q4 2024 and has held it in 7 quarters since.
  • 4,642 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Atlas Legacy Advisors's 13F filing for Q2 2026, filed 31 Jul 2026.